Your browser doesn't support javascript.
loading
Present and Future of Parkinson's Disease in Spain: PARKINSON-2030 Delphi Project.
Santos García, Diego; Blázquez-Estrada, Marta; Calopa, Matilde; Escamilla-Sevilla, Francisco; Freire, Eric; García Ruiz, Pedro J; Grandas, Francisco; Kulisevsky, Jaime; López-Manzanares, Lydia; Martínez Castrillo, Juan Carlos; Mir, Pablo; Pagonabarraga, Javier; Pérez-Errazquin, Francisco; Salom, José María; Tijero, Beatriz; Valldeoriola, Francesc; Yáñez, Rosa; Avilés, Arantxa; Luquín, María-Rosario.
Afiliação
  • Santos García D; Department of Neurology, Complexo Universitario de A Coruña (CHUAC), C/As Xubias 84, 15006 A Coruña, Spain.
  • Blázquez-Estrada M; Department of Neurology, Hospital Universitario Central de Asturias, Avenida de Roma s/n, 33011 Oviedo, Spain.
  • Calopa M; Neurology Service, Hospital Universitari de Bellvitge, 08907 Barcelona, Spain.
  • Escamilla-Sevilla F; Unidad de Trastornos del Movimiento, Servicio de Neurología, Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria ibs. Granada, 18013 Granada, Spain.
  • Freire E; Departamento de Neurología, Hospital IMED Elche, Calle Max Planck 3, 03203 Elche, Spain.
  • García Ruiz PJ; Servicio de Neurología, Fundación Jiménez Díaz, Avda Reyes Católicos 2, 28040 Madrid, Spain.
  • Grandas F; Servicio de Neurología, Hospital Gregorio Marañón, Calle del Dr. Esquerdo 46, 28007 Madrid, Spain.
  • Kulisevsky J; Servicio de Neurología, Unidad de Trastornos del Movimiento, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, CIBERNED, C/Mas Casanovas 90, 08041 Barcelona, Spain.
  • López-Manzanares L; Servicio de Neurología, Hospital de la Princesa, Calle de Diego de León 62, 28006 Madrid, Spain.
  • Martínez Castrillo JC; Servicio de Neurología, IRYCIS, Hospital Universitario Ramón y Cajal, M-607, km. 9, 100, 28034 Madrid, Spain.
  • Mir P; Servicio de Neurología, Unidad de Trastornos del Movimiento, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, CIBERNED, C/Mas Casanovas 90, 08041 Barcelona, Spain.
  • Pagonabarraga J; Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Av. Manuel Siurot, S/n, 41013 Sevilla, Spain.
  • Pérez-Errazquin F; Servicio de Neurología, Unidad de Trastornos del Movimiento, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, CIBERNED, C/Mas Casanovas 90, 08041 Barcelona, Spain.
  • Salom JM; Servicio de Neurología, Hospital Virgen de la Victoria, Campus de Teatinos, S/N, 29010 Málaga, Spain.
  • Tijero B; Servicio de Neurología, Hospital Clínico Universitario de Valencia, Avda Blasco Ibañez No. 17, 46010 Valencia, Spain.
  • Valldeoriola F; Servicio de Neurología, Hospital Cruces, Cruces Plaza, S/N, 48903 Barakaldo, Bilbao, Spain.
  • Yáñez R; Parkinson's Disease and Movement Disorders Unit-Neurology Service, Hospital Clinic Barcelona, Universitat de Barcelona & Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/Casanova 170, 08036 Barcelona, Spain.
  • Avilés A; CIBERNED, C/Mas Casanova 170, 08041 Barcelona, Spain.
  • Luquín MR; Servicio de Neurología, Complejo Hospitalario Universitario de Ourense, Ramon Puga Noguerol 54, 32005 Ourense, Spain.
Brain Sci ; 11(8)2021 Jul 31.
Article em En | MEDLINE | ID: mdl-34439646
ABSTRACT
Parkinson's disease (PD) is a chronic progressive and irreversible disease and the second most common neurodegenerative disease worldwide. In Spain, it affects around 120.000-150.000 individuals, and its prevalence is estimated to increase in the future. PD has a great impact on patients' and caregivers' lives and also entails a substantial socioeconomic burden. The aim of the present study was to examine the current situation and the 10-year PD forecast for Spain in order to optimize and design future management strategies. This study was performed using the modified Delphi method to try to obtain a consensus among a panel of movement disorders experts. According to the panel, future PD management will improve diagnostic capacity and follow-up, it will include multidisciplinary teams, and innovative treatments will be developed. The expansion of new technologies and studies on biomarkers will have an impact on future PD management, leading to more accurate diagnoses, prognoses, and individualized therapies. However, the socio-economic impact of the disease will continue to be significant by 2030, especially for patients in advanced stages. This study highlighted the unmet needs in diagnosis and treatment and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Risk_factors_studies Idioma: En Revista: Brain Sci Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Risk_factors_studies Idioma: En Revista: Brain Sci Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Espanha